Patents by Inventor Joann Bohn

Joann Bohn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CETP inhibitors
    Patent number: 8193365
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: June 5, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle Taylor, Christopher Thompson, Nazia Quraishi
  • CETP INHIBITORS
    Publication number: 20100249024
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Application
    Filed: June 14, 2010
    Publication date: September 30, 2010
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi
  • CETP inhibitors
    Patent number: 7737295
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: June 15, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle E. Taylor, Christopher F. Thompson, Nazia Quraishi
  • Cetp Inhibitors
    Publication number: 20070225365
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Application
    Filed: April 8, 2005
    Publication date: September 27, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter Sinclair, Gayle Taylor, Christopher Thompson, Nazia Quraishi